已收盤 11-20 16:00:00 美东时间
-1.190
-4.75%
Zenas BioPharma granted 225,000 stock options and 9,000 RSUs to new employees as inducement grants under Nasdaq Rule 5635(c)(4). The stock options have a $27.93 exercise price and vest over four years, while RSUs vest in four annual installments. The grants are subject to continued employment and governed by the 2026 Inducement Plan. Zenas is a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, advancing the...
11-18 21:15
Zenas BioPharma announced findings from patient and healthcare professional surveys highlighting differences in perceptions of IgG4-related disease (IgG4-RD) burden, treatment goals, and management. Patients reported higher levels of worry, underestimation of disease impact, and delayed diagnosis compared to healthcare professionals' perceptions. The findings also revealed gaps in discussions about treatment goals and emotional well-being between...
11-17 12:00
An update from Zenas BioPharma, Inc. ( ($ZBIO) ) is now available. Zenas BioPha...
11-07 05:53
Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(1.33) by 24.06 percent. This is a 35.25 percent decrease over losses of $(1.22) per share from the same period last year. The company reported $10.000 million in sales this q...
11-05 20:51
Zenas BioPharma reported Q3 2026 financial results with $647.1M in cash, cash equivalents, and investments, and a net loss of $108.9M. The company highlighted progress on its lead product obexelimab, with FDA and EMA submissions for IgG4-RD treatment, upcoming data presentations, and Phase 2 SunStone results in SLE expected in Q4 2026. Orelabrutinib Phase 3 trials in MS are ongoing, and ZB021 Phase 1 data is anticipated in Q4 2026. Jerald Korn wa...
11-05 12:00
– Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab – – Additional analyses of secondary endpoints showed that significantly fewer patients experienced clinically meaningful cumulative glucocorticoid toxicity at week 52 – – Initial open-label extensi...
10-12 19:07
Zenas BioPharma announced new data on obexelimab for IgG4-RD, showing sustained flare protection, reduced glucocorticoid toxicity, and preserved vaccine responses during a treatment-free window. The Phase 3 INDIGO open-label extension demonstrated a 93% probability of remaining flare-free at 12 months and significantly fewer patients experiencing glucocorticoid toxicity. Initial vaccine sub-study results indicated robust immune responses to influ...
10-12 11:00
Zenas BioPharma will host a virtual R&D event on October 27, 2026, to discuss its pipeline, including obexelimab (a bifunctional monoclonal antibody for systemic lupus erythematosus) and ZB021 (an oral IL-17AA/AF inhibitor). Dr. Joseph F. Merola will provide insights into the biology and clinical considerations. The event will include presentations by the management team and a live webcast available on the company's website.
10-06 11:05
今日重点评级关注:Ascendiant Capital:维持Aytu BioPharma"买入"评级,目标价从14.5美元升至15美元;摩根大通:维持Annexon"超配"评级,目标价从14美元升至15美元
10-01 19:18
HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $44 price target.
09-30 18:29